Different doses of NNC0662-0419 for lowering blood sugar in type 2 diabetes
Tests NNC0662-0419 against semaglutide or placebo in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
Key facts
- Where
- A Estrada, Barcelona, Castilleja De La Cuesta, Girona, and Santiago de Compostela, SpainSee the 6 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07415954, who can take part
Where in Spain
- Centro de Salud A EstradaA Estrada, SpainNo longer taking part
- Equip D'atencio Primaria Barcelona Sardenya S.L.P.Barcelona, SpainNo longer taking part
- Projectes Sanitaris I Socials S.A.Barcelona, SpainNo longer taking part
- Hospital Nisa Sevilla AljarafeCastilleja De La Cuesta, SpainNo longer taking part
- Clinica Bofill S.L.Girona, SpainNo longer taking part
- Centro de Saúde Concepción ArenalSantiago de Compostela, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07415954EU 2025-523260-20-00
- Record updated
- 11 September 2026
- Original description
This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.Read full original descriptionShow less
Efficacy and Safety of Once-weekly Subcutaneous NNC0662-0419 in Participants With Type 2 Diabetes - a Dose-finding Study
This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.
Inclusion: Male or female (sex at birth); Age 18-75 years (both inclusive) at the time of signing the informed consent; Glycated haemoglobin (HbA1c) of 7.0-10.0 percent (%) (53-86 millimoles per mole [mmol/mol]) (both inclusive) as assessed by central laboratory at screening; Willingness to obtain a high weight loss (greater than [>] 25% of weight at baseline).
Exclusion: Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed; Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination; Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's Questionnaire.